Price Alert

Takeda Pharmaceutical Li... (TAK)

NYSE: TAK · Real-Time Price · USD

15.28

0.01 (0.07%)

At close: Sep 09, 2025, 10:10 AM

Takeda Pharmaceutical Statistics

Share Statistics

Takeda Pharmaceutical has 3.16B shares outstanding. The number of shares has increased by -0.25% in one year.

Shares Outstanding	3.16B
Shares Change (YoY)	-0.25%
Shares Change (QoQ)	-0.73%
Owned by Institutions (%)	4.49%
Shares Floating	3.12B
Failed to Deliver (FTD) Shares	19
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 8.17M, so 0.26% of the outstanding shares have been sold short.

Short Interest	8.17M
Short % of Shares Out	0.26%
Short % of Float	0.26%
Short Ratio (days to cover)	1.93

Valuation Ratios

The PE ratio is 66.33 and the forward PE ratio is 0.19. Takeda Pharmaceutical's PEG ratio is -2.57.

PE Ratio	66.33
Forward PE	0.19
PS Ratio	1.56
Forward PS	0
PB Ratio	1.03
P/FCF Ratio	8.36
PEG Ratio	-2.57

Financial Ratio History

Enterprise Valuation

Takeda Pharmaceutical has an Enterprise Value (EV) of 8,260.6B.

EV / Sales	1.8
EV / EBITDA	6.82
EV / EBIT	7.81
EV / FCF	9.65

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.73.

Current Ratio	1.01
Quick Ratio	0.52
Debt / Equity	0.73
Debt / EBITDA	4.19
Debt / FCF	5.92
Interest Coverage	2.49

Financial Efficiency

Return on Equity is 1.56% and Return on Invested Capital is 1.72%.

Return on Equity	1.56%
Return on Assets	0.76%
Return on Invested Capital	1.72%
Revenue Per Employee	$92.97M
Profits Per Employee	$2.19M
Employee Count	49,281
Asset Turnover	0.32
Inventory Turnover	1.3

Taxes

Income Tax	66.94B
Effective Tax Rate	38.23%

Stock Price Statistics

The stock price has increased by 2.69% in the last 52 weeks. The beta is 0.27, so Takeda Pharmaceutical's price volatility has been higher than the market average.

Beta	0.27
52-Week Price Change	2.69%
50-Day Moving Average	14.82
200-Day Moving Average	14.35
Relative Strength Index (RSI)	57.99
Average Volume (20 Days)	3,538,941

Income Statement

In the last 12 months, Takeda Pharmaceutical had revenue of 4,581.6B and earned 107.93B in profits. Earnings per share was 34.17.

Revenue	4,581.6B
Gross Profit	3,001.3B
Operating Income	342.59B
Net Income	107.93B
EBITDA	1,210.5B
EBIT	449.12B
Earnings Per Share (EPS)	34.17

Full Income Statement

Balance Sheet

The company has 385.11B in cash and 5,066.2B in debt, giving a net cash position of -4,681.1B.

Cash & Cash Equivalents	385.11B
Total Debt	5,066.2B
Net Cash	-4,681.1B
Retained Earnings	1,187.6B
Total Assets	14,004.5B
Working Capital	343.54B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1,057.2B and capital expenditures -200.79B, giving a free cash flow of 856.39B.

Operating Cash Flow	1,057.2B
Capital Expenditures	-200.79B
Free Cash Flow	856.39B
FCF Per Share	266.73

Full Cash Flow Statement

Margins

Gross margin is 65.51%, with operating and profit margins of 7.48% and 2.36%.

Gross Margin	65.51%
Operating Margin	7.48%
Pretax Margin	3.82%
Profit Margin	2.36%
EBITDA Margin	26.42%
EBIT Margin	7.48%
FCF Margin	18.69%

Dividends & Yields

TAK pays an annual dividend of $0.6, which amounts to a dividend yield of 4.05%.

Dividend Per Share	$0.60
Dividend Yield	4.05%
Dividend Growth (YoY)	-5.56%
Payout Ratio	207.6%
Earnings Yield	1.51%
FCF Yield	23.92%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for TAK.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$170.85
Lynch Upside	1018.13%
Graham Number	2556.31
Graham Upside	16629.78%

Scores

Altman Z-Score	0.57
Piotroski F-Score	8